Cisatracurium Injection, Solution
Product Images NDC 63323-418

13 FDA label images from Fresenius Kabi Usa, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Cisatracurium (NDC 63323-418). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cisatr-struc-01.jpg (Cisatr Struc 01)

Cisatr-struc-01.jpg (Cisatr Struc 01)
Chemical structure of Cisatracurium besylate, depicting the arrangement of its molecular components including aromatic rings, methoxy groups, and sulfonate groups.*
FDA Label Image

Cisat-img-01.jpg (Cisat Img 01)

Cisat-img-01.jpg (Cisat Img 01)
A scatter plot chart depicting percentage changes in heart rate (HR) on the vertical axis and mean arterial pressure (MAP) on the horizontal axis, both ranging from -60% to +60%. Multiple data points are clustered near the center, indicating minor variations in HR and MAP.*
FDA Label Image

Cisat-img-02.jpg (Cisat Img 02)

Cisat-img-02.jpg (Cisat Img 02)
A scatter plot chart showing individual data points depicting the relationship between changes in mean arterial pressure (MAP) and heart rate (HR), each axis ranging from -60% to +60%. The points are clustered near the origin with some spread along both axes, illustrating variability in these cardiovascular measures.*
FDA Label Image

Cisat-img-03.jpg (Cisat Img 03)

FDA Label Image

Cisat-label-01.jpg (Cisat Label 01)

Cisat-label-01.jpg (Cisat Label 01)
Label for Cisatracurium Besylate Injection, USP 10 mg (base) per 5 mL (2 mg/mL) solution for intravenous injection. Single-dose vial, preservative-free, labeled by Fresenius Kabi USA. Includes a warning about paralytic effects and respiratory arrest, storage conditions, and handling instructions.*
FDA Label Image

Cisat-label-02.jpg (Cisat Label 02)

Cisat-label-02.jpg (Cisat Label 02)
The packaging label for Cisatracurium Besylate Injection, USP displays the 10 mg per 5 mL concentration (2 mg/mL) and indicates it is for intravenous injection. It contains 10 single-dose vials of 5 mL each. The label includes warnings about paralyzing agent use, storage conditions, preparation instructions, and manufacturer details for Fresenius Kabi USA, LLC. A barcode and NDC number 63323-416-05 are also shown.*
FDA Label Image

Cisat-label-03.jpg (Cisat Label 03)

Cisat-label-03.jpg (Cisat Label 03)
Label for Cisatracurium Besylate Injection, USP, 2 mg per mL, indicating intravenous use only. The label includes fields for date, time, and administrator, and instructions to peel off and apply the label to a syringe. The label background is red with black text.*
FDA Label Image

Cisat-label-04.jpg (Cisat Label 04)

Cisat-label-04.jpg (Cisat Label 04)
Cisatracurium Besylate Injection, USP 2 mg/mL (20 mg per 10 mL) in a multiple dose vial for intravenous injection. The label notes 0.9% benzyl alcohol as a preservative and includes warnings about its paralyzing effects and need for artificial respiration availability. Manufactured by Fresenius Kabi USA, LLC.*
FDA Label Image

Cisat-label-05.jpg (Cisat Label 05)

Cisat-label-05.jpg (Cisat Label 05)
Cisatracurium Besylate Injection, USP, 2 mg per mL (20 mg per 10 mL) in a 10 x 10 mL multiple dose vial package. The label states the formulation includes 0.9% benzyl alcohol as a preservative for intravenous injection, Rx only, manufactured by Fresenius Kabi USA, LLC. Storage and warning information is also visible on the label.*
FDA Label Image

Cisat-label-06.jpg (Cisat Label 06)

Cisat-label-06.jpg (Cisat Label 06)
Label for Cisatracurium Besylate injection, USP, 2 mg/mL strength. The label states it is for intravenous use only and contains benzyl alcohol. It includes fields for date, time, and initials, and instructions to peel off and apply to syringe.*
FDA Label Image

Cisat-label-07.jpg (Cisat Label 07)

Cisat-label-07.jpg (Cisat Label 07)
Label for Cisatracurium Besylate Injection, USP, 200 mg per 20 mL (10 mg per mL) solution for intravenous injection. Single dose vial, preservative free, for ICU use only. Manufactured by Fresenius Kabi USA, LLC. Includes storage instructions and a warning that the drug is a paralyzing agent causing respiratory arrest, requiring immediate availability of artificial respiration.*
FDA Label Image

Cisat-label-08.jpg (Cisat Label 08)

Cisat-label-08.jpg (Cisat Label 08)
Label for Cisatracurium Besylate Injection, USP 200 mg per 20 mL (10 mg per mL) in single dose vials by Fresenius Kabi USA, LLC. The label states it is for intravenous injection and ICU use only, with 10 vials of 20 mL each. It includes warnings, storage instructions, and preservative-free status.*
FDA Label Image

Cisat-label-09.jpg (Cisat Label 09)

Cisat-label-09.jpg (Cisat Label 09)
Label for Cisatracurium Besylate injection, USP, 10 mg per mL. The label indicates it is for intravenous (IV) and ICU use only, with fields for date, time, and administering person. Instructions to peel off and apply to syringe are visible. The label is printed on a red background.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.